Two intravenous (IV) doses of the antibiotic dalbavancin spaced seven days apart are just as effective at treating complicated Staphylococcus aureus bloodstream infections as daily IV doses of conventional antibiotics given over a period of four to
The US market expansion through the introduction of new products in the gastrointestinal, pain management, and digestive health division’s propelled the company's reported revenue of Rs. 620 crore, up 5% year over year
The Food Industry has been requested by the Central Government to maintain ethical standards in food advertisement and labelling for the protection of the public health and consumers' confidence.
Max Healthcare Institute Ltd. is set to invest Rs 6,000 crore by 2028 to significantly expand its hospital network across India, adding 3,700 new beds. This move will grow its current setup of 22 hospitals, which have around 5,000 beds, to about...
Cohance Lifesciences, a premier pharmaceutical company from India, is investing $10 million to improve cGMP bioconjugation capabilities in the United States. The investment will further strengthen the company’s position in the biologics and ADC...
Indoco Remedies Ltd. has obtained final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application
US pharmaceutical giant Eli Lilly stepped up competition with rival Danish drugmaker Novo Nordisk on Wednesday by introducing its popular diabetes medication Mounjaro in the Indian market. KwikPen is a single patient use prefilled pen intended for on
Senores Pharmaceuticals Limited, its wholly-owned US subsidiary Senores Pharmaceuticals, Inc., has entered into a pact to acquire two USFDA-approved Abbreviated New Drug Applications (ANDAs) of Teva Pharmaceuticals USA, Inc.
Cohance Lifesciences Limited, the partner of choice for global innovative pharma companies, announces Rs. 23 crore investments and good progress on construction of its new cGMP oligonucleotide building block manufacturing facility located in
Zydus Lifesciences, a leading Indian pharmaceutical, is preparing to launch semaglutide variants, the active ingredient in antidiabetic and weight-loss drugs, as the patent nears expiration in 2026. The firm is expected to invest over ?100...
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")